🚀 VC round data is live in beta, check it out!
Celon Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Celon Pharma and similar public comparables like Abeona Therapeutics, Amarin Corp, Duopharma Biotech, Hansa Biopharma and more.
Celon Pharma Overview
About Celon Pharma
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
Founded
2002
HQ
Employees
297
Website
Sectors
Financials (LTM)
EV
$318M
Celon Pharma Financials
Celon Pharma reported last 12-month revenue of $71M and EBITDA of $7M.
In the same LTM period, Celon Pharma generated $7M in EBITDA and had net loss of ($13M).
Revenue (LTM)
Celon Pharma P&L
In the most recent fiscal year, Celon Pharma reported revenue of $62M and EBITDA of $8M.
Celon Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $71M | XXX | $62M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $32M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $7M | XXX | $8M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 13% | XXX | XXX | XXX |
| EBIT Margin | (9%) | XXX | (6%) | XXX | XXX | XXX |
| Net Profit | ($13M) | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | (18%) | XXX | (4%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Celon Pharma Stock Performance
Celon Pharma has current market cap of $315M, and enterprise value of $318M.
Market Cap Evolution
Celon Pharma's stock price is $5.84.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $318M | $315M | 0.2% | XXX | XXX | XXX | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCelon Pharma Valuation Multiples
Celon Pharma trades at 4.5x EV/Revenue multiple, and 43.7x EV/EBITDA.
EV / Revenue (LTM)
Celon Pharma Financial Valuation Multiples
As of April 18, 2026, Celon Pharma has market cap of $315M and EV of $318M.
Equity research analysts estimate Celon Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celon Pharma has a P/E ratio of (24.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $315M | XXX | $315M | XXX | XXX | XXX |
| EV (current) | $318M | XXX | $318M | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 43.7x | XXX | 38.2x | XXX | XXX | XXX |
| EV/EBIT | (47.2x) | XXX | (78.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 10.1x | XXX | XXX | XXX |
| P/E | (24.8x) | XXX | (117.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (33.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Celon Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Celon Pharma Margins & Growth Rates
Celon Pharma's revenue in the last 12 month grew by 12%.
Celon Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Celon Pharma's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celon Pharma's rule of X is 77% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Celon Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 99% | XXX | (58%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 77% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Celon Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Celon Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Abeona Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Amarin Corp | XXX | XXX | XXX | XXX | XXX | XXX |
| Duopharma Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Hansa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Northwest Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celon Pharma M&A Activity
Celon Pharma acquired XXX companies to date.
Last acquisition by Celon Pharma was on XXXXXXXX, XXXXX. Celon Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Celon Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCelon Pharma Investment Activity
Celon Pharma invested in XXX companies to date.
Celon Pharma made its latest investment on XXXXXXXX, XXXXX. Celon Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Celon Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Celon Pharma
| When was Celon Pharma founded? | Celon Pharma was founded in 2002. |
| Where is Celon Pharma headquartered? | Celon Pharma is headquartered in Poland. |
| How many employees does Celon Pharma have? | As of today, Celon Pharma has over 297 employees. |
| Is Celon Pharma publicly listed? | Yes, Celon Pharma is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Celon Pharma? | Celon Pharma trades under CLN ticker. |
| When did Celon Pharma go public? | Celon Pharma went public in 2017. |
| Who are competitors of Celon Pharma? | Celon Pharma main competitors are Abeona Therapeutics, Amarin Corp, Duopharma Biotech, Hansa Biopharma. |
| What is the current market cap of Celon Pharma? | Celon Pharma's current market cap is $315M. |
| What is the current revenue of Celon Pharma? | Celon Pharma's last 12 months revenue is $71M. |
| What is the current revenue growth of Celon Pharma? | Celon Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Celon Pharma? | Current revenue multiple of Celon Pharma is 4.5x. |
| Is Celon Pharma profitable? | Yes, Celon Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Celon Pharma? | Celon Pharma's last 12 months EBITDA is $7M. |
| What is Celon Pharma's EBITDA margin? | Celon Pharma's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Celon Pharma? | Current EBITDA multiple of Celon Pharma is 43.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.